Surgical Robotics Company Remebot Completes RMB 430 Million Series D Financing

This round of financing was led by Zhongguancun Longmen Fund, with follow-on investments from Matrix Partners China, CCMC, Xinding Capital, Heyin Capital, and other funds.

Remebot Announces Completion of RMB 430 Million Series D FinancingRemebot, a medical surgical robotics company, announced the completion of its RMB 430 million Series D financing round. The round was led by Zhongguancun Longmen Fund, with participation from existing investors including Matrix Partners China, CCMC, Xinding Capital, and Heyin Capital. The company stated that it will invest at least RMB 300 million in the market promotion of its “Remi” neurosurgical surgical robot and in strengthening its upstream and downstream industry chain layout. Additionally, at least RMB 100 million will be allocated to the promotion and partnership development of its new product, the dental implant robot.

Liu Da, Founder, Chairman, and CEOstated that high-quality investors and substantial capital injection will further consolidate the company's leading position in the field of medical surgical robots. In the future, the company will adhere to independent innovation, continuously develop new products, establish a comprehensive product portfolio, and provide minimally invasive, precise, and efficient medical surgical robot products and services.

Nie Zhi, Co-founder and CFOStated that, building on over 20 years of R&D and the accumulation of experience from tens of thousands of neurosurgical procedures with robotic systems, the team has rapidly responded to market demands by launching China’s first dental implant robotics product. This product can effectively reduce physicians’ learning curves and enhance the standardization and automation of dental implant procedures. While new products and strategic directions present both opportunities and challenges, we are confident in our ability, with the support of clinicians, to serve the millions of patients receiving dental implants annually and to contribute to the advancement of the industry.

 Liu Zhishuo, Founding Partner of Zhongguancun Longmen Investment Fundindicates，Investing in high-quality, technology-driven enterprises during their growth phase within specialized sectors is one of Longmen Fund’s long-term investment strategies. As a leading player in the surgical robotics industry, Remebot stands at the forefront in terms of product quality, clinical implementation, and future product pipeline planning. The team is focused, professional, and entrepreneurial, possessing the qualities of an industry leader. We are optimistic about the company’s future development and believe it will continue to drive the advancement of China’s medical robotics industry. Longmen Fund remains committed to supporting leading companies in becoming industry champions and creating long-term social value together with its portfolio companies.

Li Hui, Managing Director of CCMC Capitalindicates，China Capital Management Co., Ltd. has long maintained a bullish outlook on the broad market prospects for surgical robots, leveraging CCMC’s proven track record in investment and IPOs within this sector. We highly commend the core team’s professional expertise in surgical robotics, as well as their years of accumulated operational excellence and global vision. We recognize the company’s sustained capacity for independent innovation and technological iteration, built over more than two decades, and are confident that it can deliver minimally invasive, high-efficiency surgical robotic solutions in fields such as neurosurgery and dental implantology, thereby better serving patients. China Capital Management Co., Ltd. will leverage its successful investment and investment banking experience in the surgical robotics sector to facilitate the company’s swift access to the capital markets.

Matrix Partners Chinaindicate，Novel medical devices driven by software algorithms represent a key strategic focus for MPCi in the digital healthcare sector. Surgical robots, integrating technologies such as image fusion and navigation positioning, enable minimally invasive procedures, enhance surgical precision, reduce operation time, and promote accessibilityThere are clear and strong industry drivers across multiple dimensions, including at the primary care level. Remebot boasts a top-tier team in China’s surgical robotics sector, with profound technological and R&D expertise in neurosurgery, dental implantology, and other fields. Its clinical application and commercialization are at the industry’s forefront. We look forward to the company’s continued innovation and rapid growth, creating greater value for patients and physicians alike.

Xinding CapitalChairman Zhang Chiindicate，Remebot is a leading surgical robotics enterprise in China. The surgical robotics sector is a deep-tech industry that demands sustained R&D investment over many years, aligning with Xinding Capital’s long-standing philosophy of investing in hard technology. Xinding Capital highly values the company’s years of focused and continuous R&D investment, is optimistic about its strategic direction and current product portfolio, and is committed to accompanying the enterprise for long-term mutual growth and expansion!

Union CapitalFounding Partner & Chairman Han YuzeIndicates，Minimally invasive, safe, and effective precision surgery represents the major trend in the future development of healthcare. Remebot boasts China’s top-tier robotic technology and a specialized clinical team,andProcess20Years of R&Dand accumulation, it is this persistence that has driven Lianchuang toCompleted Series C investment in the company in 2018。Looking ahead, the company isActively expanding into fields such as dentistry and spinal surgery, the company is applying for China’s first regulatory approval for a dental implant robot, following its achievement of securing the country’s first registration certificate for a neurosurgical robot. Lianchuang Capital will continue to support the development of high-end medical device technologies in China and facilitate Remebot’s rapid growth, thereby benefiting more patients.

Robotics Institute, Beihang UniversityHonorary Director Professor Wang Tianmiaoindicate，Due to minimally invasive precision, supportAIWith standout features such as surgical navigation and planning, surgical robots have become a strategic battleground where the world’s major medical giants are vying to invest in development or pursue mergers and acquisitions. Remebot’s neurosurgical robotic system has successfully completed over 10,000 procedures in numerous hospitals across China.# Fine Neurosurgery, becoming a widely recognized industry-leading innovative enterprise,CompanyLayoutofOral Implantation Robotthen targeting a broader market. We believe that under the leadership of Dr. Liu Da,With the support of numerous renowned institutions,The company willStriving for Excellence, Continuous Innovation, deeply cultivating the Chinese market and gradually expanding globally！